Carol Harrington
Primary Care · Independence, MONPI 1124018437
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,392, 8.6 times the $161 reported in 2021. Among primary care clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $94.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$565
- Abbott$486
- Teva Pharmaceuticals USA, Inc.$472
- Novo Nordisk$466
- Edwards Lifesciences$287
- Averitas Pharma Inc.$247
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $565 |
| Abbott | 4 | $486 |
| Teva Pharmaceuticals USA, Inc. | 5 | $472 |
| Novo Nordisk | 7 | $466 |
| Edwards Lifesciences | 3 | $287 |
| Averitas Pharma Inc. | 2 | $247 |
| Johnson & Johnson | 2 | $207 |
| Lundbeck LLC | 3 | $145 |
| Lilly USA, LLC | 2 | $135 |
| Medtronic | 1 | $133 |
| Neurocrine Biosciences, Inc. | 1 | $127 |
| Tempus AI, Inc | 1 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $124 |
| AbbVie | 1 | $121 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Scpharmaceuticals Inc. | 1 | $120 |
| Novartis | 1 | $117 |
| Otsuka America Pharmaceutical, Inc. | 1 | $107 |
| Idorsia Pharmaceuticals US Inc | 1 | $97 |
| Amgen | 1 | $80 |
| Viiv Healthcare Company | 1 | $74 |
| Siemens Medical Solutions USA, Inc. | 1 | $66 |
| Eisai Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$466
- Qutenza$247
- AIRSUPRA$245
- Austedo XR$245
- Edwards SAPIEN 3 Transcatheter Heart Valve$153
- NA$133
- INGREZZA$127
- FASENRA$125
- UZEDY$125
- NURTEC ODT$124
- Mavyret$121
- ZEPBOUND$120
- FUROSCIX$120
- Auvelity$120
- XARELTO$119
- Wegovy$118
- Saxenda$118
- LEQVIO$117
- Ozempic$112
- SAPIEN 3 Ultra RESILIA$108
How this compares
$4,444 in reported general payments places this provider in the 95th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $86,752 |
| OzempicSemaglutide | 29 | $68,049 |
| EliquisApixaban | 49 | $46,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $42,294 |
| RybelsusSemaglutide | 14 | $35,739 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $23,754 |
| TrulicityDulaglutide | 11 | $17,938 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $16,943 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $16,365 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $8,859 |
| LinzessLinaclotide | 14 | $7,846 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $6,631 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 121 | $6,411 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,699 |
| Gabapentin | 179 | $3,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $466 | $120,73158 claims |
| Lilly USA, LLCTrulicity | $135 | $17,93811 claims |
| AstraZenecaBreztri Aerosphere | $565 | $16,36511 claims |
| AbbVieLinzess | $121 | $7,84614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 primary care providers in Missouri.
Other primary care in Independence
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
- Taylor HeathSparta$3K
- Ashley TitchenalSaint Louis$3K
- Avonne RosarioKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.